Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Patients who lost weight with Eli Lilly's weight-loss drug, Zepbound, eventually regained a significant amount of weight after discontinuing the treatment. These findings were published in the journal JAMA. Shed light on the challenges faced by individuals seeking long-term weight management solutions.
Weight Regain Among Obese Patients
Reuters reported that the study showed that patients with obesity and no diabetes experienced a 14% weight regain nearly a year after transitioning from an eight-month course of Zepbound to a placebo. However, patients who continued the treatment witnessed an additional 5.5% reduction in weight during the 52 weeks.
Sold under the brand name Zepbound for weight loss and known as Mounjaro for type 2 diabetes, Lilly's tirzepatide has emerged as a viable option for individuals struggling with weight management. Tirzepatide, along with Novo Nordisk's Wegovy and Ozempic, belongs to a class of obesity and weight loss treatments that target the GLP-1 hormone.
Risks of Discontinuing Weight-Loss Drugs
Patients who discontinue the use of weight-loss drugs, such as Wegovy, risk regaining their original body weight within approximately five years, as per Bloomberg. Individuals must consider extended therapy with GLP-1 drugs to maximize the long-term benefits of such treatments.
Analysts have underscored the need for extended data evaluation to assess the effects of tirzepatide and other incretin-based therapies after multiple years of continuous treatment. It is essential to gain insights into potential rapidly diminishing responses to these drugs, ensuring better understanding and managing patient weight.
Throughout the 88-week treatment period, patients who continued taking Lilly's drug showcased an impressive 25.3% reduction in weight. In contrast, patients who switched to a placebo after 56 weeks experienced an overall weight reduction of 9.9% during the entire study period.
GLP-1 receptor agonists, including those offered by Novo Nordisk and Eli Lilly, have demonstrated efficacy in inducing a feeling of fullness after eating and slowing gastric emptying. These drugs present a promising approach to address the challenges individuals face in striving for effective weight management.
Photo: Towfiqu barbhuiya/Unsplash
